MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$109,374K
Net Income
-$19,032K
Net Profit Margin
-17.40%
EPS
-$0.06
Unit: Thousand (K) dollars
Revenue Breakdown
Royalty
Commercial Supply Agreement-Unit...
Furoscix
Others
Revenue Breakdown
Product Revenue
Royalty
Service
Revenue Breakdown
Product
Royalty
Commercial Supply Agreement-Unit...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
109,374
90,171
111,955
82,130
Cost of goods sold - commercial, excluding amortization of acquired intangible assets
14,409
7,509
13,927
4,498
Cost of revenue
15,131
9,964
18,726*
15,705
Research and development
18,001
17,231
27,588
14,063
Selling, general and administrative
58,302
54,085
58,411
29,088
Amortization of acquired intangible assets
4,367
4,367
993*
-
(loss) gain on foreign currency transaction
486
1,318
3
120
Total expenses
109,724
91,838
119,642
63,234
(gain) income from operations
-350
-1,667
-7,687
18,896
Interest income, net
1,022
1,429
1,637
2,628
Interest expense
11,894
7,478
7,536
1,364
Impairment of available-for-sale investment
-
-
757*
6,409
Loss on settlement of debt
-
-917
-
-
Interest expense on liability for sale of future royalties
510
2,563
3,885
3,514
Other expense
-4,992
-2,777
-252*
-
interest expense on financing liability
2,414
2,393
2,451
2,456
Total other expense
-18,788
-14,699
-13,244
-11,115
(gain) income before income tax expense
-19,138
-16,366
-20,931
7,781
Income tax (benefit) expense
-106
253
-4,983
-204
Net (gain) income
-19,032
-16,619
-15,948
7,985
Basic EPS
-0.06
-0.05
-0.052
0.03
Diluted EPS
-0.06
-0.05
-0.051
0.03
Basic Average Shares
309,191,000
308,267,000
307,315,000
306,806,000
Diluted Average Shares
309,191,000
308,267,000
312,429,000
311,638,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
3
Net (gain) income
-$19,032K
(-2949.10%↓ Y/Y)
Income tax (benefit)
expense
-$106K
(-138.97%↓ Y/Y)
Commercial Supply
Agreement-United Therapeutics...
$29,599K
License
Agreement-United Therapeutics...
$4,923K
Amphastar-Co Promotion
Agreement
$500K
(gain) income before
income tax expense
-$19,138K
(-2135.96%↓ Y/Y)
License And Service
$35,022K
Royalty
$32,370K
Furoscix
$22,191K
Afrezza
$17,021K
VGo
$2,770K
Total other expense
-$18,788K
(-331.02%↓ Y/Y)
(gain) income from
operations
-$350K
(-106.61%↓ Y/Y)
Interest income, net
$1,022K
(-44.21%↓ Y/Y)
Total revenues
$109,374K
(42.92%↑ Y/Y)
Interest expense
$11,894K
(4073.33%↑ Y/Y)
Other expense
-$4,992K
interest expense on
financing liability
$2,414K
(-0.78%↓ Y/Y)
Total expenses
$109,724K
(54.05%↑ Y/Y)
Interest expense on
liability for sale of...
$510K
(-85.32%↓ Y/Y)
(loss) gain on foreign
currency transaction
$486K
(109.06%↑ Y/Y)
Selling, general and
administrative
$58,302K
(84.37%↑ Y/Y)
Research and development
$18,001K
(31.63%↑ Y/Y)
Cost of revenue
$15,131K
(-5.20%↓ Y/Y)
Cost of goods sold -
commercial, excluding...
$14,409K
(212.76%↑ Y/Y)
Amortization of acquired
intangible assets
$4,367K
Buy us a coffee
MANNKIND CORP (MNKD)
MANNKIND CORP (MNKD)